To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study
Assessment of the progression of Parkinsons disease: a metabolic network approach
10.1093/emboj/18.7.1815 89 SpiegelbergD.MortensenA

Disclosures: takayuki tokunaga: Nothing to Disclose, Kazuhiro Sugi: Nothing to Disclose, Koichi Kudo: Nothing to Disclose, Yoshinari Sakai: Nothing to Disclose, Shiho Miyase: Nothing to Disclose, Kotaro Fukubayashi: Nothing to Disclose, Masakuni Tateyama: Nothing to Disclose, Kentaro Tanaka: Nothing to Disclose, Satoshi Narahara: Nothing to Disclose, Hiroki Inada: Nothing to Disclose, Etsuko Iio: Nothing to Disclose, Yoko Yoshimaru: Nothing to Disclose, Takehisa Watanabe: Nothing to Disclose, Katsuya Nagaoka: Nothing to Disclose, Hiroko Setoyama: Nothing to Disclose, Yasuhito Tanaka: Nothing to Disclose 1824 UBE2D3 NEGATIVELY REGULATES HEPATOCARCINOGENESIS VIA SUPPRESSION OF STAT3 SIGNALING Hideharu Nagasawa 1 Takahiro Kodama 2 Kazuki Maesaka 2 Kumiko Shirai 2 Akira Doi 2 Yuki Tahata 3 Yoshinobu Saito 4 Hayato Hikita 4 Tomohide Tatsumi 3 Tetsuo Takehara 3 , 1 Department of Gastroenterology and Hepatology, Graduate Scho, 2 University of Osaka, 3 Osaka University, 4 Osaka University Graduate School of Medicine Background: Pharmacotherapy for hepatocellular carcinoma (HCC) has progressed markedly in recent years, with many drugs becoming available
